KATP channel therapeutics at the bedside

A. Jahangir, Andre Terzic

Research output: Contribution to journalReview article

92 Scopus citations

Abstract

The family of potassium channel openers regroups drugs that share the property of activating adenosine triphosphate-sensitive potassium (K ATP) channels, metabolic sensors responsible for adjusting membrane potential-dependent functions to match cellular energetic demands. K ATP channels, widely represented in metabolically-active tissue, are heteromultimers composed of an inwardly rectifying potassium channel pore and a regulatory sulfonylurea receptor subunit, the site of action of potassium channel opening drugs that promote channel activity by antagonizing ATP-induced pore inhibition. The activity of KATP channels is critical in the cardiovascular adaptive response to stress, maintenance of neuronal electrical stability, and hormonal homeostasis. Thereby, KATP channel openers have a unique therapeutic spectrum, ranging from applications in myopreservation and vasodilatation in patients with heart or vascular disease to potential clinical use as bronchodilators, bladder relaxants, islet cell protector, antiepileptics and promoters of hair growth. While the current experience in practice with potassium channel openers remains limited, multitude of ongoing investigations aims at defining the benefit of this emerging family of therapeutics in diverse disease conditions associated with metabolic distress.

Original languageEnglish (US)
Pages (from-to)99-112
Number of pages14
JournalJournal of Molecular and Cellular Cardiology
Volume39
Issue number1
DOIs
StatePublished - Jul 2005

Keywords

  • ATP-sensitive K channels
  • Alopecia
  • Angina pectoris
  • Asthma
  • Hypertension
  • Impotence
  • Ischemic heart disease
  • Kir6.1
  • Kir6.2
  • Neuroprotection
  • Peripheral vascular disease
  • SUR1
  • SUR2

ASJC Scopus subject areas

  • Molecular Biology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'K<sub>ATP</sub> channel therapeutics at the bedside'. Together they form a unique fingerprint.

  • Cite this